ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
30 Avril 2024 - 2:32PM
Business Wire
New ingredient collaboration debuts Solgar’s
first NAD+ boosting supplement and reinforces NIAGEN as the gold
standard in the NAD+ supplement category
ChromaDex Corp. (NASDAQ:CDXC), the global authority on
nicotinamide adenine dinucleotide (NAD+) and healthy aging
research, announces an ingredient partnership with Solgar®, a
Nestlé Health Science brand. Solgar’s inaugural NAD+ supplement,
Solgar Cellular Nutrition Cellular Energy, features ChromaDex’s
patented nicotinamide riboside (NR) ingredient, NIAGEN® to support
NAD+ levels for cellular health. This product marks a significant
milestone in the health and wellness industry by combining
ChromaDex’s industry-leading NAD+ research with Solgar’s
longstanding reputation for scientifically backed supplements.
“NIAGEN NR is a testament to our dedication to the highest
scientific rigor and quality standards. This ingredient partnership
with Nestlé Health Science and Solgar is a powerful alliance to
advance healthy aging for all,” said Rob Fried, CEO of ChromaDex
and Founder of Tru Niagen.
NAD+ is an essential coenzyme that plays a vital role in
cellular functions, including mitochondrial function, cellular
energy production, and DNA repair. NIAGEN NR, the most efficient
NAD+ precursor, is backed by two Nobel Prize winners, 30+ human
clinical studies, 300 published scientific studies, has been
accepted by the world’s most rigorous regulatory bodies, and 300mg
of NIAGEN NR is clinically shown to increase NAD+ by over 50% in
two weeks.
Solgar Cellular Energy features 300mg of NIAGEN NR to support
cell energy, repair, and vitality. Solgar Cellular Energy helps
renew the body’s natural ability to transform nutrients into energy
– the energy cells need each day. In addition to NIAGEN NR, the
product features a blend of six B vitamins (B1, B2, B6, B12,
Biotin, and Pantothenic Acid) and vitamin C for immune, heart, and
nerve health, delivering a holistic approach to healthy aging.
ChromaDex’s Mona Rosene, MS, RD, Director of Scientific Affairs,
was recently interviewed by Solgar Cellular Nutrition to discuss
the science behind NAD+ and NIAGEN NR, which can be read on the
Solgar website.
Solgar’s Cellular Energy supplement featuring NIAGEN NR is
available as part of a suite of Cellular Nutrition products. To
read more about the science supporting NIAGEN NR visit
www.chromadex.com and for more information on the Solgar Cellular
Nutrition Cellular Energy product featuring NIAGEN NR, please visit
www.solgar.com/cellular-nutrition.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on
nicotinamide adenine dinucleotide (NAD+), with a focus on the
science of healthy aging. The ChromaDex team, comprised of
world-renowned scientists, works with independent investigators
from esteemed universities and research institutions around the
globe to uncover the full potential of NAD+. A vital coenzyme found
in every cell of the human body, NAD+ declines with age and
exposure to other everyday stressors. NAD+ depletion is a
contributor to age-related changes in health and vitality. Setting
the benchmark as the gold standard in scientific rigor, safety,
quality, and transparency, ChromaDex is the innovator behind its
clinically proven flagship ingredient, NIAGEN® (patented
nicotinamide riboside, or NR), the most efficient and
superior-quality NAD+ booster available.
NIAGEN NR is the active ingredient in ChromaDex’s consumer
products, sold as the brand Tru Niagen®, the number one
healthy-aging NAD+ supplement in the United States*. Clinically
proven to increase NAD+ levels, Tru Niagen is helping people around
the world transform the way they age (available at
www.truniagen.com). ChromaDex’s robust patent portfolio protects NR
and other NAD+ precursors. ChromaDex maintains a website at
www.chromadex.com, to which ChromaDex regularly publishes copies of
its press releases, news, and financial information.
*Based on the top-selling dietary supplement brands by revenue
per the largest U.S. e-commerce marketplace (as of
3/1/2023-2/29/2024).
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to Solgar Cellular Nutrition
Cellular Energy Supplement marking a significant milestone in the
health and wellness industry. Statements that are not a description
of historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects," "anticipates," "intends," "estimates," "plans,"
"potential," "possible," "probable," "believes," "seeks," "may,"
"will," "should," "could" or the negative of such terms or other
similar expressions. Risks that contribute to the uncertain nature
of these forward-looking statements include the impact of the
COVID-19 pandemic on our business and the global economy; our
history of operating losses and need to obtain additional
financing; the growth and profitability of our product sales; our
ability to maintain sales, marketing and distribution capabilities;
changing consumer perceptions of our products; our reliance on a
single or limited number of third-party suppliers; and the risks
and uncertainties associated with our business and financial
condition. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2023, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
Source: ChromaDex Corporation
*These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure or prevent any disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430870400/en/
ChromaDex Media Contact: Kendall Knysch, Head of Media
Relations & Partnerships 310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: +1 (949) 356-1620
InvestorRelations@ChromaDex.com
ChromaDex (NASDAQ:CDXC)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ChromaDex (NASDAQ:CDXC)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024